You’re the worst! — EWB POAP #3
2021-12-24
Sometimes it’s hard to find that perfect gift that balances those complicated feelings of love and loathing. Designed by the Bathwater (@thebeefwater) this POAP is the perfect way to show your enemy your true feelings. Grab yours today.
We (NFT Chinese Community) launched an event on November 11, 2021, and established the DAO initial team, in order to commemorate this extraordinary moment and inspire us to move forward, the first 60 members (including 10 of the Twitter event) can receive POAP. Twitter:@iNFTnews; Telegram:https://t.me/iNFTnews; Website:www.inftnews.com Date: November 11; Method: Manual distribution.
Yat Discord 50k Watch Party
2021-12-10
In December 2021 we celebrated our 50,000 member to join the Yat Chat Discord community. Thanks for being there with us, and being a part of the first 50k! Join the Yat Chat Discord Server at http://discord.gg/yat
Pukenza Voter!
2021-12-10
Voted for Pukenza's preliminary vote on snapshot? Claim your POAP now! Holders of the Pukenza Voter POAP can enter a raffle for a chance to win 10 custom Pukenza backgrounds from L3xc of https://degenartclub.com/ Raffle date: 3rd December Friday, 7pm Pacific Time. Claim your POAP and enter the raffle here https://poap.fun/raffle/917 Please DM @itsmechase on Twitter if you've voted on snapshot but you're unable to claim the POAP.
This Week In VNFT 12/7/21
2021-12-08
This attendance token is to commemorate and reward our most active listeners for this week of VNFT 12/7/21
docPEACE; Host of GOLDen MetaSessions with docPEACE, the first radio show to feature only NFT creatives, including Ja Rule. Doctor of Pharmacy by trade and Spoken Word Artist at heart, docPEACE has flowed on legendary stages, including Gary Vee's. As a Conscious Connections Speaker, Consultant, and best-selling author docPEACE helps NFT enthusiasts claim their GOLD through conscious connections and business development.
A memento to remember the things you learned. In this video, we reviewed the phase 1 clinical trial of molnupiravir, a broad-spectrum antiviral oral medication developed by Ridgeline Therapeutics. These data show the safety profile and pharmacokinetics of molnupiravir for the first time in humans.
